• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Efficacy and safety of less invasive surfactant administration in the treatment of neonatal respiratory distress syndrome: a Meta analysis].微创表面活性剂给药治疗新生儿呼吸窘迫综合征的疗效与安全性:一项Meta分析
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Jul;22(7):721-727. doi: 10.7499/j.issn.1008-8830.2001043.
2
Less invasive surfactant administration versus intubation-surfactant-extubation in the treatment of neonatal respiratory distress syndrome: a systematic review and meta-analyses.经鼻持续气道正压通气与常规间歇正压通气治疗早产儿呼吸窘迫综合征的临床疗效比较
J Pediatr (Rio J). 2024 Jan-Feb;100(1):8-24. doi: 10.1016/j.jped.2023.05.008. Epub 2023 Jun 21.
3
The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants.表面活性剂给药技术(肺内滴注法与气管插管-肺表面活性物质给药法)对早产儿呼吸窘迫综合征治疗结局的影响。
Dev Period Med. 2019;23(3):163-171. doi: 10.34763/devperiodmed.20192303.163171.
4
Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis.早期经气管内给予皮质类固醇和肺表面活性物质预防新生儿呼吸窘迫综合征早产儿支气管肺发育不良的 Meta 分析。
Curr Med Sci. 2019 Jun;39(3):493-499. doi: 10.1007/s11596-019-2064-9. Epub 2019 Jun 17.
5
Efficacy and safety of surfactant administration via thin catheter in preterm infants with neonatal respiratory distress syndrome: A systematic review and meta-analysis.经细导管给予表面活性剂治疗新生儿呼吸窘迫综合征早产儿的疗效和安全性:一项系统评价和荟萃分析。
Pediatr Pulmonol. 2021 Sep;56(9):3013-3025. doi: 10.1002/ppul.25545. Epub 2021 Jul 2.
6
Effects of less invasive surfactant administration versus intubation-surfactant-extubation on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome: a single-center, retrospective study from China.经鼻持续气道正压通气与肺表面活性物质联合鼻塞式气道正压通气治疗早产儿呼吸窘迫综合征的临床疗效比较 目的:探讨经鼻持续气道正压通气(NCPAP)与肺表面活性物质(PS)联合鼻塞式气道正压通气(CPAP)治疗早产儿呼吸窘迫综合征(NRDS)的临床疗效。方法:选择 2019 年 1 月至 2020 年 12 月在我院接受治疗的 86 例 NRDS 早产儿作为研究对象,按照随机数字表法分为观察组和对照组,每组 43 例。观察组给予 NCPAP 联合 PS 治疗,对照组给予 CPAP 联合 PS 治疗。比较两组患儿的临床疗效、血气指标、机械通气时间、住院时间及不良反应发生情况。结果:观察组患儿的总有效率为 95.35%,明显高于对照组的 76.74%(P<0.05)。治疗后,观察组患儿的 PaO2、SaO2 水平明显高于对照组,PaCO2 水平明显低于对照组(P<0.05)。观察组患儿的机械通气时间和住院时间明显短于对照组(P<0.05)。观察组患儿的不良反应总发生率为 4.65%,明显低于对照组的 18.60%(P<0.05)。结论:NCPAP 联合 PS 治疗 NRDS 早产儿的临床疗效优于 CPAP 联合 PS 治疗,能有效改善血气指标,缩短机械通气时间和住院时间,降低不良反应发生率。
BMC Pulm Med. 2022 Dec 5;22(1):462. doi: 10.1186/s12890-022-02270-x.
7
Surfactant administration methods for premature newborns: LISA vs. INSURE comparative analysis.表面活性物质给药方法用于早产儿:LISA 与 INSURE 比较分析。
J Neonatal Perinatal Med. 2024;17(2):233-239. doi: 10.3233/NPM-230194.
8
Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial.经鼻给予肺表面活性物质与气管内给予肺表面活性物质后行小潮气量通气治疗中国呼吸窘迫综合征早产儿的随机对照试验研究方案
Trials. 2020 Jun 11;21(1):516. doi: 10.1186/s13063-020-04390-3.
9
Less Invasive Surfactant Administration for the Treatment of Neonatal Respiratory Distress Syndrome Combined With Noninvasive Ventilation in Anhui Province, China: A Retrospective Cohort Study.中国安徽省应用微创肺泡表面活性物质治疗新生儿呼吸窘迫综合征合并无创通气的回顾性队列研究。
Clin Pediatr (Phila). 2023 Oct;62(9):1109-1117. doi: 10.1177/00099228231152859. Epub 2023 Feb 7.
10
Surfactant administration in preterm babies (28-36 weeks) with respiratory distress syndrome: LISA versus InSurE, an open-label randomized controlled trial.表面活性物质在有呼吸窘迫综合征的早产儿(28-36 周)中的应用:LISA 与 InSurE,一项开放标签随机对照试验。
Pediatr Pulmonol. 2023 Mar;58(3):738-745. doi: 10.1002/ppul.26246. Epub 2022 Dec 1.

引用本文的文献

1
Clinical evaluation of serum miR-513a-3p combined with arterial blood gas analysis parameters and lung ultrasound score in neonatal respiratory distress syndrome.血清 miR-513a-3p 联合动脉血气分析参数及肺部超声评分对新生儿呼吸窘迫综合征的临床评估。
Ital J Pediatr. 2024 Oct 29;50(1):227. doi: 10.1186/s13052-024-01795-7.
2
The association of serum vitamin D level and neonatal respiratory distress syndrome.血清维生素 D 水平与新生儿呼吸窘迫综合征的关系。
Ital J Pediatr. 2023 Jan 30;49(1):16. doi: 10.1186/s13052-023-01415-w.
3
Value of Serum miR-34a and Ang-1 in Severity Evaluation and Prognosis of Neonatal Respiratory Distress Syndrome.血清miR-34a和血管生成素-1在新生儿呼吸窘迫综合征严重程度评估及预后中的价值
Emerg Med Int. 2022 Sep 21;2022:5480026. doi: 10.1155/2022/5480026. eCollection 2022.
4
Efficacy and safety of nasal intermittent positive pressure ventilation and nasal continuous positive airway pressure ventilation in neonatal respiratory distress syndrome: a systematic review and meta-analysis.经鼻间歇正压通气与经鼻持续气道正压通气治疗新生儿呼吸窘迫综合征的疗效与安全性:一项系统评价和荟萃分析
Transl Pediatr. 2022 Jul;11(7):1242-1250. doi: 10.21037/tp-22-288.
5
Reintubation rates after extubation to different non-invasive ventilation modes in preterm infants.早产儿拔管后不同无创通气模式下的再插管率。
BMC Pediatr. 2021 Jun 16;21(1):281. doi: 10.1186/s12887-021-02760-7.

本文引用的文献

1
[Risk factors for minimally invasive surfactant administration failure in preterm infants with respiratory distress syndrome].[呼吸窘迫综合征早产儿微创表面活性剂给药失败的危险因素]
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Mar;22(3):231-237. doi: 10.7499/j.issn.1008-8830.2020.03.010.
2
The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants.表面活性剂给药技术(肺内滴注法与气管插管-肺表面活性物质给药法)对早产儿呼吸窘迫综合征治疗结局的影响。
Dev Period Med. 2019;23(3):163-171. doi: 10.34763/devperiodmed.20192303.163171.
3
Less invasive surfactant administration (LISA): chances and limitations.经鼻给予表面活性物质(LISA):机会与限制。
Arch Dis Child Fetal Neonatal Ed. 2019 Nov;104(6):F655-F659. doi: 10.1136/archdischild-2018-316557. Epub 2019 Jul 11.
4
Novel Surfactant Administration Techniques: Will They Change Outcome?新型表面活性剂给药技术:会改变结局吗?
Neonatology. 2019;115(4):411-422. doi: 10.1159/000497328. Epub 2019 Apr 11.
5
European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update.欧洲呼吸窘迫综合征管理共识指南-2019 更新版。
Neonatology. 2019;115(4):432-450. doi: 10.1159/000499361. Epub 2019 Apr 11.
6
Less Invasive Surfactant Administration in Preterm Infants with Respiratory Distress Syndrome.在患有呼吸窘迫综合征的早产儿中进行的微创表面活性剂给药
J Coll Physicians Surg Pak. 2019 Mar;29(3):226-330. doi: 10.29271/jcpsp.2019.03.226.
7
The use of less invasive surfactant administration (LISA) in the United States with review of the literature.美国使用微创表面活性剂给药(LISA)并文献复习。
J Perinatol. 2019 Mar;39(3):426-432. doi: 10.1038/s41372-018-0302-9. Epub 2019 Jan 11.
8
Less invasive surfactant administration and complications of preterm birth.经更少侵袭性的表面活性剂给药和早产的并发症。
Sci Rep. 2018 May 29;8(1):8333. doi: 10.1038/s41598-018-26437-x.
9
Treatment and outcome data of very low birth weight infants treated with less invasive surfactant administration in comparison to intubation and mechanical ventilation in the clinical setting of a cross-sectional observational multicenter study.在一项横断面观察性多中心研究的临床环境中,与气管插管和机械通气相比,接受较少有创性肺表面活性剂治疗的极低出生体重儿的治疗和结局数据。
Eur J Pediatr. 2018 Aug;177(8):1207-1217. doi: 10.1007/s00431-018-3179-x. Epub 2018 May 28.
10
Review demonstrates that less invasive surfactant administration in preterm neonates leads to fewer complications.研究表明,对早产儿进行侵入性较小的表面活性剂给药可减少并发症。
Acta Paediatr. 2018 May;107(5):736-743. doi: 10.1111/apa.14161. Epub 2018 Feb 9.

微创表面活性剂给药治疗新生儿呼吸窘迫综合征的疗效与安全性:一项Meta分析

[Efficacy and safety of less invasive surfactant administration in the treatment of neonatal respiratory distress syndrome: a Meta analysis].

作者信息

Huo Meng-Yue, Mei Hua, Zhang Yu-Heng, Liu Chun-Zhi, Hu Ya-Nan, Song Dan

机构信息

Department of Neonatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China.

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2020 Jul;22(7):721-727. doi: 10.7499/j.issn.1008-8830.2001043.

DOI:10.7499/j.issn.1008-8830.2001043
PMID:32669168
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7389609/
Abstract

OBJECTIVE

To evaluate the efficacy and safety of less invasive surfactant administration (LISA) in the treatment of neonatal respiratory distress syndrome (NRDS).

METHODS

PubMed, Cochrane Library, Embase, China Biology Medicine disc, China Scientific Journal Database, CNKI Database, and Wanfang Database were searched for randomized controlled trials (RCTs) on the use of LISA strategy in the treatment of NRDS. Literature screening and quality assessment were performed according to inclusion and exclusion criteria. Review Manager 5.3 software was used to perform the Meta analysis.

RESULTS

A total of 9 RCTs were included, with a total of 1 212 children with NRDS. There were 611 children in the experimental group (treated with LISA strategy) and 601 children in the control group [treated with intubation-surfactant-extubation (INSURE) strategy]. The Meta analysis showed that the use of LISA strategy reduced the rate of mechanical ventilation within 72 hours after birth (OR=0.39, 95%CI: 0.29-0.51, P<0.001) and the incidence rates of bronchopulmonary dysplasia (OR=0.53, 95%CI: 0.38-0.72, P<0.001) and pneumothorax (OR=0.56, 95%CI: 0.33-0.93, P=0.02). There were no significant differences in the mortality rate and incidence rates of other neonatal diseases between the two groups (P>0.05). There was no significant difference in the rate of repeated use of pulmonary surfactant (PS) between the two groups (P>0.05), but there was a higher incidence rate of PS reflux observed by LISA strategy (OR=2.60, 95%CI: 1.64-4.12, P<0.001).

CONCLUSIONS

Compared with INSURE strategy, LISA strategy has advantages in reducing the need for mechanical ventilation and the incidence rates of bronchopulmonary dysplasia and pneumothorax in children with NRDS.

摘要

目的

评估微创表面活性剂给药(LISA)治疗新生儿呼吸窘迫综合征(NRDS)的疗效和安全性。

方法

检索PubMed、Cochrane图书馆、Embase、中国生物医学光盘数据库、中国科学期刊数据库、CNKI数据库和万方数据库,查找关于使用LISA策略治疗NRDS的随机对照试验(RCT)。根据纳入和排除标准进行文献筛选和质量评估。使用Review Manager 5.3软件进行Meta分析。

结果

共纳入9项RCT,涉及1212例NRDS患儿。实验组(采用LISA策略治疗)611例,对照组[采用插管-表面活性剂-拔管(INSURE)策略治疗]601例。Meta分析显示,使用LISA策略可降低出生后72小时内机械通气率(OR=0.39,95%CI:0.29-0.51,P<0.001)、支气管肺发育不良发生率(OR=0.53,95%CI:0.38-0.72,P<0.001)和气胸发生率(OR=0.56,95%CI:0.33-0.93,P=0.02)。两组间死亡率及其他新生儿疾病发生率差异无统计学意义(P>0.05)。两组间肺表面活性物质(PS)重复使用率差异无统计学意义(P>0.05),但LISA策略观察到的PS反流发生率较高(OR=2.60,95%CI:1.64-4.12,P<0.001)。

结论

与INSURE策略相比,LISA策略在降低NRDS患儿机械通气需求、支气管肺发育不良和气胸发生率方面具有优势。